MXPA05010143A - Uso de compuestos para la prevencion de toxicidad celular inducida por farmaco. - Google Patents

Uso de compuestos para la prevencion de toxicidad celular inducida por farmaco.

Info

Publication number
MXPA05010143A
MXPA05010143A MXPA05010143A MXPA05010143A MXPA05010143A MX PA05010143 A MXPA05010143 A MX PA05010143A MX PA05010143 A MXPA05010143 A MX PA05010143A MX PA05010143 A MXPA05010143 A MX PA05010143A MX PA05010143 A MXPA05010143 A MX PA05010143A
Authority
MX
Mexico
Prior art keywords
compound
alkyl
receptor
compounds
use according
Prior art date
Application number
MXPA05010143A
Other languages
English (en)
Spanish (es)
Inventor
Anders Nykjaer
Original Assignee
Reception Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reception Aps filed Critical Reception Aps
Publication of MXPA05010143A publication Critical patent/MXPA05010143A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05010143A 2003-03-26 2004-03-25 Uso de compuestos para la prevencion de toxicidad celular inducida por farmaco. MXPA05010143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300459 2003-03-26
PCT/DK2004/000205 WO2004084876A2 (en) 2003-03-26 2004-03-25 Use of compounds for the prevention of drug-induced cell toxicity

Publications (1)

Publication Number Publication Date
MXPA05010143A true MXPA05010143A (es) 2006-03-17

Family

ID=58707224

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010143A MXPA05010143A (es) 2003-03-26 2004-03-25 Uso de compuestos para la prevencion de toxicidad celular inducida por farmaco.

Country Status (11)

Country Link
US (1) US20070004727A1 (enExample)
EP (1) EP1610773A2 (enExample)
JP (1) JP2006520761A (enExample)
CN (1) CN100441175C (enExample)
AU (1) AU2004224788A1 (enExample)
BR (1) BRPI0408699A (enExample)
CA (1) CA2560522A1 (enExample)
EA (1) EA200501518A1 (enExample)
MX (1) MXPA05010143A (enExample)
WO (1) WO2004084876A2 (enExample)
ZA (1) ZA200508482B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101076372A (zh) * 2004-10-06 2007-11-21 里斯普蒂康公司 化合物用于预防药物诱导的细胞毒性的用途
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
EP2139461A2 (en) * 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2195466T3 (da) 2007-10-01 2013-01-14 Longhorn Vaccines & Diagnostics Llc Fremgangsmåde til opbevaring af biologiske prøver
WO2012151555A1 (en) * 2011-05-04 2012-11-08 President And Fellows Of Harvard College Methods and coatings for treating biofilms
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2021117065A1 (en) * 2019-12-14 2021-06-17 Manu Chaudhary Formulations of polybasic drugs to reduce multi-organ toxicity
WO2022169690A1 (en) * 2021-02-02 2022-08-11 Yanping Kong Composition and methods for treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1364521A (en) * 1971-07-16 1974-08-21 Merck & Co Inc Aminoglycoside antibiotics
US4564325A (en) * 1983-03-14 1986-01-14 Ackerman Galen R Flush-mounted round bale mover for truck beds
US4654325A (en) * 1984-05-24 1987-03-31 Selenke William M Medicament for reducing nephrotoxicity caused by positively charged agents such as aminoglycosides and methods of use thereof
WO1989005637A1 (en) * 1987-12-22 1989-06-29 U.S. Bioscience Improving toxicity profiles in chemotherapy
US5010092A (en) * 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
US5409915A (en) * 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5658902A (en) * 1994-12-22 1997-08-19 Warner-Lambert Company Quinazolines as inhibitors of endothelin converting enzyme
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
AU8278498A (en) * 1997-07-07 1999-02-08 Cambridge Neuroscience, Inc. Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6949679B1 (en) * 1998-04-21 2005-09-27 Universite Laval Polyamine transport inhibitors
FR2797444B1 (fr) * 1999-08-13 2003-02-07 Lafon Labor Compositions pharmaceutiques comprenant des 4-quinolones
DE10053506A1 (de) * 2000-10-27 2002-05-02 Max Delbrueck Centrum Mittel zur Prävention von Organschäden, die durch Aminoglykoside induziert werden
RU2003124640A (ru) * 2001-01-08 2005-02-27 Медиквест Терапевтикс, Инк. (Us) Гидрофобные полиаминные аналоги и способы их применения
EP1478618A1 (en) * 2002-02-07 2004-11-24 Wisconsin Alumni Research Foundation Polyamine compounds and compositions for use in conjunction with cancer therapy
WO2003080103A1 (en) * 2002-04-25 2003-10-02 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents

Also Published As

Publication number Publication date
BRPI0408699A (pt) 2006-03-28
AU2004224788A1 (en) 2004-10-07
EP1610773A2 (en) 2006-01-04
WO2004084876A2 (en) 2004-10-07
JP2006520761A (ja) 2006-09-14
CA2560522A1 (en) 2004-10-07
CN100441175C (zh) 2008-12-10
CN1794982A (zh) 2006-06-28
WO2004084876A3 (en) 2004-12-23
ZA200508482B (en) 2007-03-28
EA200501518A1 (ru) 2006-04-28
US20070004727A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
CN100441175C (zh) 化合物用于制备预防药物诱导的细胞毒性药物的用途
EP2139461A2 (en) Amino derivatives to prevent nephrotoxicity and cancer
AU698881B2 (en) Compositions for treatment of chronic inflammatory diseases
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP6685991B2 (ja) 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
CA2788669C (en) Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
US20090110720A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
KR20150050595A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
ES2374399T3 (es) Piridoxamina para uso en el tratamiento de nefropatía diabética en diabetes tipo ii.
JP2023518775A (ja) シクロフィリン阻害剤およびその使用
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2010260864A (ja) 血液殺寄生虫薬
KR102651652B1 (ko) 이소성 석회화의 치료를 위한 이노시톨 포스페이트
AU2009220942B2 (en) Methods of treatment employing prolonged continuous infusion of Belinostat
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
HRP20030382A2 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US20050148519A1 (en) Salts of pharmacologically active compounds
AU2009333303A1 (en) Enema formulations
Tarloff et al. of the Kidney

Legal Events

Date Code Title Description
FA Abandonment or withdrawal